Menopause Society 2025 Data Shows Fezolinetant Eases Vasomotor Symptoms and Boosts Work Productivity
New data cuts from the OPTION-VMS study, released at The Menopause Society 2025 meeting, show that fezolinetant—marketed as Veozah—significantly reduces the frequency and severity of hot flashes and night sweats while improving daily workplace productivity.
Clinical Trial Replication and Early Symptom Relief
The initial OPTION-VMS data cut confirms that the therapeutic benefits observed in earlier SKYLIGHT trials translate directly to real-world patient populations. While the primary time point for measuring vasomotor symptom bother using the MENQOL scale was set at 12 weeks, Maki noted that meaningful improvements emerged much earlier. Patients reported measurable relief in hot flash bother at 4 weeks and 8 weeks, indicating an early onset of therapeutic benefit.
Measurable Gains in Workplace Productivity
Beyond symptom reduction, the study tracked functional outcomes that affect daily living. Women enrolled in the trial reported a substantial boost in workplace productivity within the 12-week study window. Participants also experienced marked improvements in activity levels outside of work, demonstrating that managing vasomotor symptoms directly translates to enhanced functional capacity in everyday life.
Frequently Asked Questions About OPTION-VMS and Veozah
What specific tool was used to measure hot flash bother?
Researchers used the MENQOL (Menopause-Specific Quality of Life) questionnaire, which is a widely validated instrument designed to measure vasomotor symptom bother in menopausal women.
When did patients first report noticeable improvements in the trial?
While 12 weeks served as the primary evaluation time point, patients reported measurable improvements in hot flash bother as early as 4 weeks and 8 weeks after starting treatment.
Related reading